An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers ; day:13 ; month:03 ; year:2024 ; extent:16
Advanced science ; (13.03.2024) (gesamt 16)

Creator: Yu, Yueh‐Hsiang
Tian, Wei‐Ting
Grauffel, Cédric
Lin, Wei‐Chen
Hsieh, Ming‐Yu
Wu, Pei‐Wen
Lee, Hui‐Ju
Peng, Chi‐Jiun
Lin, Pei‐Hsuan
Chu, Hsing‐Mao
Lim, Carmay
Chang, Tse Wen

DOI: 10.1002/advs.202307852

URN: urn:nbn:de:101:1-2024031314041981054070

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:44 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Yu, Yueh‐Hsiang
Tian, Wei‐Ting
Grauffel, Cédric
Lin, Wei‐Chen
Hsieh, Ming‐Yu
Wu, Pei‐Wen
Lee, Hui‐Ju
Peng, Chi‐Jiun
Lin, Pei‐Hsuan
Chu, Hsing‐Mao
Lim, Carmay
Chang, Tse Wen

Other Objects (12)

The First FDA-Approved Antibody-Drug Conjugate

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate

$Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma$

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

$Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study$

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice

Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma

Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates

Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein

The First FDA-Approved Antibody-Drug Conjugate

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate

$Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma$

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

$Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study$

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice

Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma

Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates

Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein

The First FDA-Approved Antibody-Drug Conjugate

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate

$Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma$

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

$Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study$

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice

Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma

Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates

Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

The First FDA-Approved Antibody-Drug Conjugate

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice

Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma

Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates

Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein

The First FDA-Approved Antibody-Drug Conjugate

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice

Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma

Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates

Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein

The First FDA-Approved Antibody-Drug Conjugate

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice

Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma

Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates

Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein

Related objects

Reset password